{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:47:49Z","timestamp":1790812069767,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["1R01HD094380-01"],"award-info":[{"award-number":["1R01HD094380-01"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alliance for NanoHealth"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s43032-020-00248-w","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T19:03:16Z","timestamp":1594062196000},"page":"271-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-132X","authenticated-orcid":false,"given":"Mostafa A.","family":"Borahay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Motamedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Tekedereli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salama A.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Ozpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan S.","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"4","key":"248_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bpobgyn.2008.04.002","volume":"22","author":"S Okolo","year":"2008","unstructured":"Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571\u201388.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"248_CR2","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1210\/jc.2008-2093","volume":"94","author":"AV Hoekstra","year":"2009","unstructured":"Hoekstra AV, Sefton EC, Berry E, Lu Z, Hardt J, Marsh E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab. 2009;94(5):1768\u201374.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"248_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1055\/s-0037-1606303","volume":"35","author":"K Fritton","year":"2017","unstructured":"Fritton K, Borahay MA. New and emerging therapies for uterine fibroids. Semin Reprod Med. 2017;35(6):549\u201359. https:\/\/doi.org\/10.1055\/s-0037-1606303.","journal-title":"Semin Reprod Med"},{"key":"248_CR4","first-page":"1","volume":"51","author":"HHS Keshavarz","year":"2002","unstructured":"Keshavarz HHS, Kieke BA, Marchbanks PA. Hysterectomy surveillance\u2014United States, 1994-1999. MMWR CDC Surveill Summ. 2002;51:1\u20138.","journal-title":"MMWR CDC Surveill Summ"},{"issue":"4","key":"248_CR5","first-page":"593","volume":"51","author":"PT Mannisto","year":"1999","unstructured":"Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 1999;51(4):593\u2013628.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"248_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ijc.20473","volume":"112","author":"J Dobos","year":"2004","unstructured":"Dobos J, Timar J, Bocsi J, Burian Z, Nagy K, Barna G, et al. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer. 2004;112(5):771\u20136. https:\/\/doi.org\/10.1002\/ijc.20473.","journal-title":"Int J Cancer"},{"issue":"3 Pt 1","key":"248_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1158\/1078-0432.CCR-05-2068","volume":"12","author":"GE Garcia","year":"2006","unstructured":"Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, et al. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res. 2006;12(3 Pt 1):980\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2068.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"248_CR8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1593\/neo.05145","volume":"7","author":"F Sato","year":"2005","unstructured":"Sato F, Fukuhara H, Basilion JP. Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia. 2005;7(9):838\u201346.","journal-title":"Neoplasia."},{"issue":"1","key":"248_CR9","first-page":"81","volume":"57","author":"N Klauber","year":"1997","unstructured":"Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997;57(1):81\u20136.","journal-title":"Cancer Res"},{"issue":"8","key":"248_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jsgi.2006.09.003","volume":"13","author":"SA Salama","year":"2006","unstructured":"Salama SA, Nasr AB, Dubey RK, Al-Hendy A. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006;13(8):542\u201350. https:\/\/doi.org\/10.1016\/j.jsgi.2006.09.003.","journal-title":"J Soc Gynecol Investig"},{"issue":"10","key":"248_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007356","volume":"4","author":"SA Salama","year":"2009","unstructured":"Salama SA, Kamel MW, Botting S, Salih SM, Borahay MA, Hamed AA, et al. Catechol-o-methyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling in leiomyoma cells. PLoS One. 2009;4(10):e7356.","journal-title":"PLoS One"},{"issue":"1","key":"248_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.fertnstert.2012.04.002","volume":"98","author":"SA Salama","year":"2012","unstructured":"Salama SA, Diaz-Arrastia CR, Kilic GS, Kamel MW. 2-Methoxyestradiol causes functional repression of transforming growth factor beta3 signaling by ameliorating Smad and non-Smad signaling pathways in immortalized uterine fibroid cells. Fertil Steril. 2012;98(1):178\u201384. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.04.002.","journal-title":"Fertil Steril"},{"issue":"1","key":"248_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10637-006-9008-5","volume":"25","author":"J James","year":"2007","unstructured":"James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Investig New Drugs. 2007;25(1):41\u20138. https:\/\/doi.org\/10.1007\/s10637-006-9008-5.","journal-title":"Investig New Drugs"},{"issue":"4","key":"248_CR14","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/sj.bjc.6601591","volume":"90","author":"CR Ireson","year":"2004","unstructured":"Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer. 2004;90(4):932\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6601591.","journal-title":"Br J Cancer"},{"issue":"11","key":"248_CR15","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1039\/c1mb05143a","volume":"7","author":"L Simeone","year":"2011","unstructured":"Simeone L, Mangiapia G, Irace C, Di Pascale A, Colonna A, Ortona O, et al. Nucleolipid nanovectors as molecular carriers for potential applications in drug delivery. Mol BioSyst. 2011;7(11):3075\u201386. https:\/\/doi.org\/10.1039\/c1mb05143a.","journal-title":"Mol BioSyst"},{"issue":"1","key":"248_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2796.2009.02191.x","volume":"267","author":"B Ozpolat","year":"2010","unstructured":"Ozpolat B, Sood AK, Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010;267(1):44\u201353. https:\/\/doi.org\/10.1111\/j.1365-2796.2009.02191.x.","journal-title":"J Intern Med"},{"issue":"2","key":"248_CR17","first-page":"292","volume":"6","author":"B Ozpolat","year":"2003","unstructured":"Ozpolat B, Lopez-Berestein G, Adamson P, Fu CJ, Williams AH. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci. 2003;6(2):292\u2013301.","journal-title":"J Pharm Pharm Sci"},{"key":"248_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.addr.2013.12.008","volume":"66","author":"B Ozpolat","year":"2014","unstructured":"Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110\u20136. https:\/\/doi.org\/10.1016\/j.addr.2013.12.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"248_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IJN.S26766","volume":"7","author":"HI Chang","year":"2012","unstructured":"Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49\u201360. https:\/\/doi.org\/10.2147\/IJN.S26766.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"248_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4155\/tde.12.144","volume":"4","author":"H Ali","year":"2013","unstructured":"Ali H, Kilic G, Vincent K, Motamedi M, Rytting E. Nanomedicine for uterine leiomyoma therapy. Ther Deliv. 2013;4(2):161\u201375. https:\/\/doi.org\/10.4155\/tde.12.144.","journal-title":"Ther Deliv"},{"issue":"13","key":"248_CR21","doi-asserted-by":"publisher","first-page":"16619","DOI":"10.18632\/oncotarget.7672","volume":"7","author":"Z Hamurcu","year":"2016","unstructured":"Hamurcu Z, Ashour A, Kahraman N, Ozpolat B. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016;7(13):16619\u201335. https:\/\/doi.org\/10.18632\/oncotarget.7672.","journal-title":"Oncotarget"},{"key":"248_CR22","doi-asserted-by":"publisher","first-page":"196.e1","DOI":"10.1016\/j.ajog.2015.03.055","volume":"213","author":"MA Borahay","year":"2015","unstructured":"Borahay MA, Vincent K, Motamedi M, Sbrana E, Kilic GS, Al-Hendy A, et al. Novel effects of simvastatin on uterine fibroids: in vitro and patient-derived Xenograft mouse model study. Am J Obstet Gynecol. 2015;213:196.e1\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2015.03.055.","journal-title":"Am J Obstet Gynecol"},{"key":"248_CR23","first-page":"53","volume":"324","author":"M Ito","year":"2008","unstructured":"Ito M, Kobayashi K, Nakahata T. NOD\/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol Immunol. 2008;324:53\u201376.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1\u20132","key":"248_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijpharm.2009.09.045","volume":"384","author":"B Du","year":"2010","unstructured":"Du B, Li Y, Li X, Youmei A, Chen C, Zhang Z. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm. 2010;384(1\u20132):140\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.09.045.","journal-title":"Int J Pharm"},{"issue":"5","key":"248_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1700\/989.10728","volume":"97","author":"B Du","year":"2011","unstructured":"Du B, Wang SY, Shi XF, Zhang CF, Zhang ZZ. The effect of 2-methoxyestradiol liposome on growth inhibition, angiogenesis and expression of VEGF and Ki67 in mice bearing H22 hepatocellular carcinoma. Tumori. 2011;97(5):660\u20135. https:\/\/doi.org\/10.1700\/989.10728.","journal-title":"Tumori."},{"key":"248_CR26","doi-asserted-by":"crossref","unstructured":"Tsuiji K, Takeda T, Li B, Kondo A, Ito M, Yaegashi N. Establishment of a novel xenograft model for human uterine leiomyoma in immunodeficient mice. Tohoku J Exp Med. 222(1):55\u201361.","DOI":"10.1620\/tjem.222.55"},{"issue":"6","key":"248_CR27","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1210\/en.2009-1225","volume":"151","author":"H Ishikawa","year":"2010","unstructured":"Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433\u201342.","journal-title":"Endocrinology."},{"issue":"4","key":"248_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3892\/ijo.2011.1304","volume":"40","author":"MA Hossain","year":"2012","unstructured":"Hossain MA, Kim DH, Jang JY, Kang YJ, Yoon JH, Moon JO, et al. Aspirin induces apoptosis in vitro and inhibits tumor growth of human hepatocellular carcinoma cells in a nude mouse xenograft model. Int J Oncol. 2012;40(4):1298\u2013304. https:\/\/doi.org\/10.3892\/ijo.2011.1304.","journal-title":"Int J Oncol"},{"issue":"11","key":"248_CR29","doi-asserted-by":"publisher","first-page":"e82346","DOI":"10.1371\/journal.pone.0082346","volume":"8","author":"S Nishitani","year":"2013","unstructured":"Nishitani S, Horie M, Ishizaki S, Yano H. Branched chain amino acid suppresses hepatocellular cancer stem cells through the activation of mammalian target of rapamycin. PLoS One. 2013;8(11):e82346. https:\/\/doi.org\/10.1371\/journal.pone.0082346.","journal-title":"PLoS One"},{"issue":"2","key":"248_CR30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1525-1438.2005.15220.x","volume":"15","author":"L Li","year":"2005","unstructured":"Li L, Da J, Landstrom M, Ulmsten U, Fu X. Antiproliferative activity and toxicity of 2-methoxyestradiol in cervical cancer xenograft mice. Int J Gynecol Cancer. 2005;15(2):301\u20137. https:\/\/doi.org\/10.1111\/j.1525-1438.2005.15220.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"18","key":"248_CR31","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1158\/1078-0432.CCR-05-0440","volume":"11","author":"C Sweeney","year":"2005","unstructured":"Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005;11(18):6625\u201333. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0440.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"248_CR32","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1158\/1078-0432.CCR-07-0807","volume":"13","author":"SV Rajkumar","year":"2007","unstructured":"Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007;13(20):6162\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0807.","journal-title":"Clin Cancer Res"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-020-00248-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-020-00248-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-020-00248-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T23:24:53Z","timestamp":1625527493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-020-00248-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["248"],"URL":"https:\/\/doi.org\/10.1007\/s43032-020-00248-w","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest to.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Texas Medical Branch at Galveston.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}